[
    [
        {
            "time": "2020-03-24",
            "original_text": "达成全年物业合同销售目标 中国奥园年度净利大增78%至52.2亿元",
            "features": {
                "keywords": [
                    "中国奥园",
                    "物业合同",
                    "净利",
                    "增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "房地产"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "达成全年物业合同销售目标 中国奥园年度净利大增78%至52.2亿元",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-03-26",
            "original_text": "药明康德发布《未来三年(2020年-2022年)股东回报规划》",
            "features": {
                "keywords": [
                    "药明康德",
                    "股东回报",
                    "规划"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德发布《未来三年(2020年-2022年)股东回报规划》",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-03-26",
            "original_text": "药明康德2019成绩单：营收128.72亿元，60%收入来自美国客户",
            "features": {
                "keywords": [
                    "药明康德",
                    "营收",
                    "美国客户"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德2019成绩单：营收128.72亿元，60%收入来自美国客户",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-03-26",
            "original_text": "药明康德2019年度净利润下降17.96%至18.55亿元拟10转4派3.37元 盈利能力下降",
            "features": {
                "keywords": [
                    "药明康德",
                    "净利润",
                    "下降",
                    "盈利能力"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药明康德2019年度净利润下降17.96%至18.55亿元拟10转4派3.37元 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-03-26",
            "original_text": "北向资金今日净流入39.87亿元，药明康德再获净买入3.16亿元",
            "features": {
                "keywords": [
                    "北向资金",
                    "净流入",
                    "药明康德"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "北向资金今日净流入39.87亿元，药明康德再获净买入3.16亿元",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 10,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        }
    ]
]